Abstract
The relationship between diabetes and pancreatic cancer is complex. Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients. Epidemiological studies have consistently shown a modest increase in the risk of pancreatic cancer in type 2 diabetes, with an inverse relationship to duration of disease. Additionally, recent studies suggest that anti-diabetic medications may modulate the risk of pancreatic cancer in type 2 diabetes. Subjects >50 years of age with new onset diabetes are at higher risk of having pancreatic cancer. However, to screen new-onset diabetes for pancreatic cancer, additional markers are needed that can distinguish pancreatic cancer-associated diabetes from type 2 diabetes.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Age Factors
-
Body Mass Index
-
Clinical Trials as Topic
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / epidemiology
-
Diabetes Mellitus, Type 2 / etiology*
-
Early Detection of Cancer
-
Evidence-Based Medicine
-
Global Health
-
Glucose Intolerance / complications
-
Glucose Intolerance / epidemiology
-
Glucose Intolerance / etiology*
-
Humans
-
Hyperinsulinism / complications
-
Hyperinsulinism / epidemiology
-
Hyperinsulinism / etiology*
-
Hypoglycemic Agents / adverse effects
-
Insulin Glargine
-
Insulin, Long-Acting / adverse effects
-
Meta-Analysis as Topic
-
Metformin / adverse effects
-
Obesity / complications
-
Pancreatic Neoplasms / complications*
-
Pancreatic Neoplasms / drug therapy
-
Pancreatic Neoplasms / epidemiology
-
Pancreatic Neoplasms / etiology
-
Prevalence
-
Risk Assessment
-
Risk Factors
Substances
-
Hypoglycemic Agents
-
Insulin, Long-Acting
-
Insulin Glargine
-
Metformin